Template:Pyelonephritis medical therapy: Difference between revisions
Jump to navigation
Jump to search
/* Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) Adapted from Clin Infect Dis. 2011;52(5):e103-20.{{Cite journal | last1 = Gupta | first1 = K. | last2 = Hooton | first2 = TM. | last3 = Naber | first3 = KG. | last4 = Wullt | first4 ... |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 59: | Line 59: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 3''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen 3''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 g IV q24h'''''<BR> OR <BR> ▸ '''''[[Doripenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 1 g IV q8–12h | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 g IV q24h'''''<BR> OR <BR> ▸ '''''[[Doripenem]] 500 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 1 g IV q8–12h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL> '''Antibiotics should be administered for at least 10–14 days based on local resistance patterns.''' <BR> '''De-escalation to oral antibiotcs may be considered 24–48 hours after defervescence.''' </SMALL> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL> '''Antibiotics should be administered for at least 10–14 days based on local resistance patterns.''' <BR> '''De-escalation to oral antibiotcs may be considered 24–48 hours after defervescence.''' </SMALL> | ||
Line 66: | Line 66: | ||
|} | |} | ||
|} | |} | ||
==Empiric Therapy for Acute Pyelonephritis (Pregnancy) <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''European Association of Urology's Guidelines on Urological Infections'' <ref>{{Cite web | last = | first = | title = http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | url =http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | publisher = | date = | accessdate = }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>== | ==Empiric Therapy for Acute Pyelonephritis (Pregnancy) <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''European Association of Urology's Guidelines on Urological Infections'' <ref>{{Cite web | last = | first = | title = http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | url =http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf | publisher = | date = | accessdate = }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>== |
Revision as of 04:46, 7 March 2014
Empiric Therapy for Acute Pyelonephritis (Outpatient & Inpatient) Adapted from Clin Infect Dis. 2011;52(5):e103-20.[1]
|
|
Empiric Therapy for Acute Pyelonephritis (Pregnancy) Adapted from European Association of Urology's Guidelines on Urological Infections [2]
|
References
- ↑ Gupta, K.; Hooton, TM.; Naber, KG.; Wullt, B.; Colgan, R.; Miller, LG.; Moran, GJ.; Nicolle, LE.; Raz, R. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654. Unknown parameter
|month=
ignored (help) - ↑ "http://www.uroweb.org/gls/pdf/18_Urological%20infections_LR.pdf" (PDF). External link in
|title=
(help)